{"entity":{"id":"nct07229625","kind":"trial","name":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","aka":[],"tldr":"A phase 3 trial testing SHR-8068 in biliary tract cancer, now recruiting.","summary":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) is a phase 3 interventional study registered as NCT07229625, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: A Phase III, Randomised, Controlled, Open-Label, Multicenter Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-Line Treatment for Advanced Biliary Tract Cancer (BTC). Planned enrolment is 604 participants (estimated). The study started in 2026-01-21 and primary completion is expected in 2029-12. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07229625","url":"https://clinicaltrials.gov/study/NCT07229625"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["shr-8068"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07229625","phase":"3","setting":"A Phase III, Randomized, Controlled, Open-Label, Multicenter Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-Line Treatment for Advanced Biliary Tract Cancer (BTC)","sponsor":"Suzhou Suncadia Biopharmaceuticals","participation":[{"nct":"NCT07229625","source":"https://clinicaltrials.gov/study/NCT07229625","fetchedAt":"2026-10-07T16:55:34.394Z","studySha256":"3797dba1312f31ca4e9b07cc9d8d908da22d705a29759ae8353263614975fdcc","overallStatus":"RECRUITING","lastUpdatePosted":"2026-01-28","leadSponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":604,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-01-21","startedType":"actual","enrolled":604,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07229625/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"drug":[{"id":"shr-8068","kind":"drug","name":"SHR-8068","route":"/drugs/shr-8068/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"target":[{"id":"btc","kind":"target","name":"BTC","route":"/targets/btc/"}]}}